SUNNYVALE, Calif., Sept. 17, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that leading hospitals
in Japan are using the
Radixact® System with the Synchrony®
Automatic, Real-time Motion Synchronization
Technology1 to provide advanced cancer treatments
to more patients throughout the country. The addition of Synchrony
to the Radixact System will enable the hospital teams to
efficiently deliver highly accurate radiation dose to tumors that
move as a result of bodily processes or patient movement,
minimizing the amount of healthy tissue surrounding the tumors that
are exposed to high-dose radiation, all while patients breathe
naturally – no uncomfortable patient restraints or breath-hold
techniques are required. Synchrony is the only technology
using image guidance during radiation delivery to
automatically synchronize radiation treatment in real-time with the
movement of the tumor.
Multiple sites in Japan are now
using the Radixact System with Synchrony, including Takarazuka City
Hospital in Hyogo, Japanese Red Cross Nagoya Daini Hospital in
Aichi, and Kishiwada Tokushukai Hospital in Osaka. The Synchrony technology will enable
the hospital teams to treat a wider range of cancer cases, faster
and with less harm to patients. The Takarazuka City Hospital team
treated the first Synchrony patient in Asia, and was also the first in the world to
perform a liver treatment with the innovative technology.
Japanese Red Cross Nagoya Daini Hospital replaced an existing
TomoTherapy® System with the next-generation Radixact
System. The hospital team, in partnership with Nagoya City University, led by Prof.
Yuta Shibamoto, is using the system
and the Synchrony technology to expand cancer treatment
capabilities and help improve patients' outcomes.
"Using the Radixact System with Synchrony real-time tracking
technology, SBRT at our hospital can be performed more effectively
in the lower lobes of the lung. Synchrony enables us to reduce
radiation exposure to healthy lung tissues in the lower lobe,
because we no longer have to expand the treatment field to
encompass the entire volume of tumor movement. I can confidently
recommend Radixact with Synchrony to our patients," said
Chikao Sugie, M.D., Vice Director of
Department of Radiology at Japanese Red Cross Nagoya Daini
Hospital. "The introduction of the Radixact System with Synchrony
allows us to decrease the irradiated lung volume, making the
treatment less stressful and invasive for patients, while also
reducing the procedural burden on our healthcare team. In the
future, I would like to expand the indications for treatment using
this technology to include liver SBRT, based on our positive
experience with lung SBRT and boost irradiation of advanced lung
tumors. Synchrony technology has increased the versatility of the
system and achieved automated, ultra-precise radiation therapy,
which brings exceptional value to us."
"We are very encouraged by the early adoption of our Synchrony
and Radixact System technologies by customers in Japan, the country currently with the highest
penetration of these innovative solutions in the world. We are
proud to have the opportunity to partner with such enthusiastic
clinical professionals to advance cancer care in Japan," said Suzanne
Winter, chief commercial officer and senior vice president,
R&D at Accuray. "Cancer is highly prevalent in the aging
Japanese population. Synchrony for the Radixact System will provide
clinicians with the technology they need to effectively and
efficiently treat virtually any patient requiring radiation
therapy. The combined technologies enable the delivery of radiation
using a variety of methods — from image-guided intensity-modulated
radiation therapy (IG-IMRT) to stereotactic body radiation therapy
(SBRT) — to treat almost any tumor, even those that move, with
precision, accuracy and unprecedented flexibility."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiation therapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products; the company's ability to develop
new products or improve existing products to meet customers' needs;
the company's ability to anticipate or keep pace with changes in
the marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's annual report on Form 10-K, filed
with the Securities and Exchange Commission (the "SEC") on
August 25, 2020, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1"Synchrony® Automatic, Real-time Motion
Synchronization Technology" is synonymous with the development
name: "Motion Tracking and Compensation Feature for the
Radixact® Treatment Delivery System"
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-radixact-system-with-synchrony-technology-delivers-advanced-cancer-treatments-at-multiple-hospitals-in-japan-301132962.html
SOURCE Accuray Incorporated